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Objective: To evaluate the effectiveness in diagnosing mammographically and sonographically occult breast lesions by using magnetic
resonance imaging (MRI) guided vacuum-assisted breast biopsy in patients who presented to a community-based hospital with a newly
established breast MRI program.
Methods: The records of 142 consecutive patients, median age of 55 years, who had undergone MRI-guided biopsy at our institution between
July 2006 and July 2007 were reviewed. From these patients, 197 mammographically and sonographically occult lesions were biopsied at the
time of discovery. The pathology was then reviewed and correlated with the MRI findings.
Results: Cancer was present and subsequently discovered in 8% of the previously occult lesions (16/197) or 11% of the women studied (16/
142). Of the cancerous lesions, 56% were invasive carcinomas (9/16) and 44% were ductal carcinomas in situ (7/16). Fourteen percent of the
discovered lesions (28/197) were defined as high risk and included atypical ductal hyperplasia, atypical lobular hyperplasia, lobular
carcinoma in situ, and radial scar. In total, occult cancerous and high-risk lesions were discovered in 22% of the found lesions (44/197) or
31% of the women who underwent MRI-guided biopsy (44/142).
Conclusions: This study demonstrated that detection of cancerous and high-risk lesions can be significantly increased when an MRI-guided biopsy
program is introduced at a community-based hospital. We believe that as radiologists gain confidence in imaging and histologic correlation,
community-based hospitals can achieve similar rates of occult lesion diagnosis as those found in data emerging from academic institutions.Abre´ge´
Objectif: E´valuer l’efficacite´ du diagnostic de le´sions mammaires occultes par mammographie ou par e´chographie au moyen d’une biopsie
du sein par pression ne´gative guide´e par l’imagerie par re´sonance magne´tique (IRM) chez les patientes qui se pre´sentent a` un hoˆpital
communautaire ayant nouvellement e´tabli un programme d’IRM des seins.
Me´thodes: Les dossiers de 142 patientes conse´cutives, d’aˆge me´dian de 55 ans, ayant subi une biopsie guide´e par IRM a` notre e´tablissement
entre juillet 2006 et juillet 2007 ont e´te´ revus. Dans ce groupe de patientes, 197 le´sions occultes par mammographie ou par e´chographie
e´taient biopsie´es au moment de leur de´couverte. Par la suite, l’examen pathologique a e´te´ corre´le´ aux re´sultats de l’IRM.
Re´sultats: Le cancer e´tait pre´sent et a e´te´ subse´quemment de´couvert dans 8 % des le´sions occultes (16 sur 197) ou 11 % des femmes faisant partie
de l’e´tude (16 sur 142). Parmi les le´sions cance´reuses, 56 % consistent en des carcinomes infiltrants (9 sur 16) et 44 % sont des carcinomes canalaires
in situ (7 sur 16). Quatorze pour cent (14 %) des le´sions de´couvertes (28 sur 197) ont e´te´ juge´es a` risque e´leve´ et comprenaient l’hyperplasie
canalaire atypique, l’hyperplasie lobulaire atypique, le carcinome lobulaire in situ et la cicatrice radiaire. Au total, des le´sions occultes cance´reuses
et a` haut risque ont repre´sente´ 22 % des le´sions de´couvertes (44 sur 197) ou 31 % des femmes ayant subi une biopsie guide´e par IRM (44 sur 142).
Conclusions: Cette e´tude a de´montre´ que l’e´tablissement d’un programme de biopsie guide´e par IRM dans un hoˆpital communautaire peut
conside´rablement faciliter la de´tection de le´sions cance´reuses et a` haut risque. Nous croyons qu’au fur et a` mesure que les radiologistes
prendront de l’assurance en imagerie et en corre´lation histologique, les hoˆpitaux communautaires pourront parvenir a` des re´sultats en
diagnostic de le´sions occultes semblables a` ceux exprime´s dans les donne´es provenant des e´tablissements universitaires.
 2009 Canadian Association of Radiologists. All rights reserved.
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The need for accurate early detection and diagnosis of
breast cancer has led to an increased demand for breast
magnetic resonance imaging (MRI) and percutaneous biopsy
options. Ovel et al [1] and Kriege et al [2] suggested that the
overall discriminating ability of MRI in breast cancer is
significantly better than mammography, and current esti-
mates of occult cancers subsequently discovered by using
MRI-guided breast biopsies are upward of 30% [1,2]. The
aim of our study was to investigate, in a community setting,
the role of MRI as a more sensitive imaging modality to
detect otherwise occult breast lesions compared with tradi-
tional mammography or ultrasonography.
Breast MRI is an important adjunct to the conventional
imaging modalities in the detection and assessment of primary
and recurrent breast cancers that remain mammographically,
sonographically, and clinically occult [3e6]. After a diagnosis
of breast cancer, MRI may provide a more accurate assessment
of the extent of disease than conventional modalities and
physical examination [7,8]. MRI has been successfully used to
evaluate contralateral and ipsilateral breasts recently diag-
nosed with cancer to identify multifocal or multicentric
disease [9,10]. Breast MRI has also proven successful in
evaluating post-lumpectomy and post-implant breasts, and in
screening women with high-risk factors, such as a genetic
predisposition to disease, a family history of cancer, and dense
breast composition. In addition, breast MRI has been useful in
the evaluation of patients with isolated axillary metastasis
suspect for occult primary breast cancer [11].
No longer is MRI-guided breast biopsy limited to large
academic institutions. The decreasing costs of MRI-guided
vacuum-assisted biopsy devices, combined with the greater
availability of high-quality breast MRI and well-trained
technicians has enabled many community hospitals and
imaging centers to offer MRI-guided core biopsy of the breast.
After the introduction of a breast MRI program to our
hospital, we examined MRI-guided biopsy specimens of
those lesions found to be mammographically and sono-
graphically occult. In this article, we present a retrospective
review of our initial experiences and outcomes in a commu-
nity-based hospital.
Materials and Methods
Between July 2006 and July 2007, Morristown Memorial
Hospital, Morristown, NJ, performed approximately 1,200
breast MRI studies and provided MRI-guided needle locali-
zation and biopsy for suspicious lesions. The pathologies of
the first 142 consecutive patients who underwent MRI-
guided vacuum-assisted core biopsy during the designated
study interval were retrospectively reviewed. These initial
142 MRI-guided biopsies were investigated so that we might
assess the utility of MRI breast imaging and correlate our
findings with future studies as our program developed. This
retrospective study was approved by the institutional review
board of Atlantic Health, Morristown Memorial Hospital.Patients were selected for screening or diagnostic MRI
based on clinical assessment and, in some cases, clinical
assessment and the American Cancer Society guidelines for
breast screening [12]. Multiple selection criteria were used to
determine a patient’s inclusion: newly diagnosed breast
cancer, BRCA 1 or 2 mutations, personal history or a first-
degree relative with a history of breast cancer, radiation to
the chest between the ages of 10 and 30 years, heterogeneous
or extremely dense breast tissue on mammography, a lifetime
cancer risk of 15%e20%, an indeterminate physical exam-
ination, histologic findings of atypical lobular hyperplasia
(ALH), atypical ductal hyperplasia (ADH), or lobular
carcinoma in situ (LCIS).
All 142 women, median age of 55 years, had lesions
discovered by MRI, with negative mammograms (BI-RADS 1
or 2), as indicated by the American College of Radiology Breast
Imaging and Reporting Data System (BI-RADS), 4th ed,
Reston, VA, and negative ultrasounds at least 3 months before
biopsy. Once identified with MRI, the lesion morphology was
described and correlated with the approximate size and degree
of enhancement, and the previously occult lesions were sub-
jected to additional mammography and targeted ultrasound as
a ‘‘second look.’’ Those lesions initially detected by MRI and
subsequently revealed by ‘‘second look’’studies were excluded,
as our study focused solely on lesions occult to these techniques.
If the additional imaging and ultrasound were inconclusive (the
lesion was mammographically and sonographically occult),
then a recommendation for MRI biopsy was issued. Lesions not
visualized with ‘‘second look’’ techniques underwent MRI-
guided biopsy performed by 1 of 3 breast fellowship-trained,
board-certified radiologists.
Within 6 months of their initial MRI-guided biopsy, all
patients were followed up at our institution with another
diagnostic breast MRI to document the stability of the
biopsied lesion. The histopathology of each specimen was
then reviewed. Only 1 patient had interval growth at 6
months after the MRI-guided core biopsy, which may have
been because of sampling error, and the decision was made
to remove the entire region with MRI-guided localization.
The lesion subsequently revealed ductal carcinoma in situ
(DCIS). Of the remaining 141 patients, no new diagnoses of
cancer have been reported since the writing of this article.
The decision to biopsy a specific lesion, by using MRI-
guided vacuum assistance, was multifactorial. Radiologists’
recommendations for biopsy focused on lesion morphology,
degree of enhancement, and lesion size. Physician-referred
requests for biopsy were accepted based on the physician’s
assessment of clinical risk. Clinical risk factors included the
following: family history; menopausal status; mammographic
parenchymal density; and personal breast cancer history,
subdivided into ipsilateral and contralateral breast cancer; and
a recent (within 1 year) or remote history of cancer.
MRI and Biopsy Techniques
One hundred of the studied patients were scanned by
using a 1.5-T GE Signa Excite system (GE Medical Systems,
198 P. Friedman et al. / Canadian Association of Radiologists Journal 60 (2009) 196e200Figure 1. A 48-year-old woman, considered high risk, with a positive family history of breast cancer. Mammogram (not shown) revealed increased parenchymal
density, with no suspicious findings. (A) T-1, fat-saturated, postcontrast MRI reveals an irregular area of intense enhancement in the left lower inner quadrant.
(B) Vacuum-assisted MRI-guided breast biopsy specimen reveals DCIS.Waukesha, WI). The remaining 42 patients were scanned by
using a 1.5-T Philips Intera system (Philips Medical
Systems, Best, The Netherlands). Two different breast MRI
coils were used. The 7CH InVivo Breast MRI coil (InVivo
Corporation, Orlando, FL) was used on both the Philips MRI
and GE MRI systems in our hospital practice. An 8CH-USA
Coil (GE Medical) was used at our outpatient facility on
a 1.5T GE Signa Excite MRI (GE Medical).
All acquisitions were performed in an axial plane, with
imaging bilaterally. The protocol included two-dimensional,
multislice, turbo spin-echo based T1- and T2-weighted
acquisitions. Planning of these acquisitions consisted of
thirty 5-mm-thick slices (gap, 0.5 mm), with a field of view
of 30 cm. An acquisition matrix of 512  384 was used. The
repetition times and echo times were 609 ms and 7 ms for
a T1-weighted sequence and 2600 ms and 11.5 ms for a T2-
weighted sequence, respectively.
Three-dimensional contrast-enhanced dynamic scans
were planned immediately after the two-dimensional scans.
Thirty milliliters of gadodiamide intravenous contrast
(Omniscan; Amersham Health, Oslo, Norway) were admin-
istered, acquiring 7 time points, with the first point acquired
before contrast administration, and used as a mark. The
dynamic imaging sequence was T1 weighted, with active fat
suppression. The field of view was similar to the preceding
two-dimensional acquisitions, but the slice thickness was
reduced to 2.5 mm, with 80 slices planned axially, which
yielded a repetition time and echo time of 11 ms and 5 ms,
respectively. An acquisition matrix yielded a temporal
resolution of less than 1 minute.
The MRI-guided core needle biopsies were performed by
using a 7CH InVivo biopsy breast array coil (InVivo), with
a biopsy apparatus, and the SenoRx EnCor vacuum-assisted
10-gauge MRI biopsy device (SenoRx Inc., Aliso Viejo,
CA). The MRI protocol was similar to that for diagnostic
imaging but lacked the two-dimensional T2-weighted and
isotropic acquisition. T1-weighted images were obtained inboth the axial and sagittal planes, followed by a three-
dimensional contrast dynamic scan. Each lesion was identi-
fied and biopsied by using these images, and a clip was
placed for follow-up localization if needed. Postbiopsy
mammograms were performed to guide any subsequent
surgical procedures and to ensure proper clip visualization.
Diagnostic MR images were reviewed and analysed on
a DynaCAD workstation (InVivo). The analysis was done in
accordance with the American College of Radiology guide-
lines. All studies were reviewed in conjunction with the
patient’s clinical history, as well as current and available
sonograms and mammograms.
Results
Histopathologic examination of 197 biopsied lesions from
142 patients was correlated with the respective MRI findings.
Lesion sizes ranged from a small focus of 3 mm to enhancing
areas of 40 mm. The smallest cancer localized, an invasive
ductal carcinoma, was 4 mm. The largest cancer localized, an
infiltrating lobular carcinoma, was 20 mm.
Sixteen pathologic specimens, discovered with MRI and
biopsied under MRI guidance, returned with a result positive
for cancer, giving 11% of the studied women (16/142) a new
diagnosis of breast cancer. The 16 positive pathologies
accounted for 8% of the total 197 lesions biopsied. Fifty-six
percent of these new cancers (9/16) proved to be
invasive carcinomas, with the remaining 44% identified as
DCIS (7/16) (Figure 1). Of the newly discovered lesions, 4.5%
were invasive carcinomas (9/197), whereas 3.5% were DCIS
(7/197). Invasive carcinoma was determined to be in 6% of the
women (9/142). DCIS existed in 4.9% of the women (7/142).
High-risk lesions, including ADH, ALH, and LCIS,
accounted for 14% of the pathologies (28/197) and 20% of the
women studied (28/142) (Figure 2). Benign lesions accounted
for 78% of the biopsied specimens (153/197). In total, cancer
plus high-risk lesions accounted for 22% of the newly
199Vacuum-assisted MRI-guided breast biopsy / Canadian Association of Radiologists Journal 60 (2009) 196e200Figure 2. A 50-year-old woman with known cancer of the right breast underwent MRI for evaluation of extensive disease. A ‘‘second look’’ ultrasound (not
shown) was without suspicious findings. (A) MRI of right breast demonstrates known lesion of the upper-inner right breast. (B) T-1 weighted MRI demonstrates
a 6-mm, round, intensely enhancing, retroareolar, mid-depth mass. (C) MRI-guided needle biopsy confirms atypical ductal hyperplasia.discovered lesions (44/197) or 31% of the patients (44/142)
(Table 1).
Discussion
Breast MRI has provided an exceptional level of sensitivity
to detecting breast cancers of smaller sizes and earlier stages.
In 2004, Kriege et al [2] reported the sensitivity of MRI for
detecting invasive breast cancer to be 79.5% compared with
17.9% and 33.3% sensitivities for clinical breast examination
and mammography, respectively. Despite high sensitivity,
breast MRI continues to demonstrate high rates of false posi-
tives and varied levels of specificity, calling to question its
reliability. However, the incorporation of percutaneous MRI-
guided core biopsy has provided a fast, minimally invasiveway
to obtain tissue from lesions only visualized by using MRI.
MRI-guided biopsies make it easier to justify wider use of
breast MRI by decreasing the need for surgical intervention for
lesions that have a high likelihood of being benign, confirming
a suspected diagnosis, and directing the patient and clinician
towards the proper treatment regimens.
Table 1
Histologic findings from MRI-guided core biopsya
Lesion finding
No. women
biopsied (n ¼ 142)
No. lesions
biopsied (n ¼ 197)
Benignb 98 (69%) 153 (78%)
High riskc 28 (20%) 28 (14%)
Malignant 16 (11%) 16 (8%)
DCIS 7 (5% of total,
44% of cancers)
7 (3.5% of total,
44% of cancers)
Invasive 9 (6% of total,
56% of cancers)
9 (4.5% of total,
56% of cancers)
High risk
plus malignant
44 (31%) 44 (22%)
aA total of 197 biopsies were performed on 142 women.
bIncludes fibrocystic change, fibrosis, ductal hyperplasia, fibroadenoma,
sclerosing adenosis, papilloma, stromal hyperplasia, and papilloma.
cIncludes atypical ductal hyperplasia, atypical lobular hyperplasia, LCIS,
and radial scar.As MRI-guided vacuum-assisted core biopsy becomes
more prevalent in the community, there are still many issues
related to its uses that must be standardized, including
patient-selection criteria, variation in scanning techniques
and equipment, radiologist experience, and innate difficulties
related to MRI-guided procedures, such as slice thickness, fat
saturation, and echo times [13]. Failure to collectively
resolve such issues may cause higher rates of false-positive
diagnoses and altered outcomes. Moreover, there can be
difficulties with MRI-guided biopsies, such as lesions with
visibility affected by rapid washout and lesions that may be
altered by compression or displaced by lidocaine insertion.
In these instances, the radiologist may not be able to obtain
the proper amounts of tissue and ensure accuracy.
In our retrospective study, breast MRI-guided core biopsy
found occult cancer in 11% of women (16/142) and 8% of
the lesions biopsied (16/197). These lesions were not
demonstrated on mammography or on ultrasound and would
have otherwise gone undetected and untreated at their current
stage. Of the cancers detected, approximately half of the
lesions were DCIS and half were invasive carcinoma. An
additional 20% of women had ADH, ALH, or LCIS (28/
142). From histopathology of the biopsied specimen,
combined rates of cancers and high-risk lesions were
discovered in 22% of the lesions localized (44/197), which
affected 31% of the women (44/142). Thirty-one percent of
our patients were found to have an occult cancer or high-risk
lesion. This value approximates the 1995 study by Orel et al
[1], who, by using MRI, detected occult cancers or high-risk
lesions in 34% of their studied population. Additional studies
by Liberman et al [5,14], found occult cancers and high-risk
lesions in 25% and 27% of their patients.
Our practice has trended towards detection of high-risk
lesions rather than invasive cancer or DCIS. We speculate
that this may be related to 2 issues. First, because of the
recent introduction and novelty of our breast MRI program,
our clinicians have been more reluctant to observe lesions
with serial MRI and have been more apt to order MRI-guided
biopsies to obtain tissue diagnoses. This may have urged
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followed up, thus increasing the occurrence of falsely posi-
tive findings. Second, our breast center is staffed with
fellowship-trained breast-imaging radiologists who perform
all of our own ‘‘second look’’ ultrasounds after breast MRI.
The high level of operator skill may have led to a greater rate
of cancer discovery with the ‘‘second look’’ ultrasound and
the subsequent exclusion of lesions from the study.
Our experience with MRI of the breast supports literature
findings that MRI is a valuable tool in the early detection of
cancer and high-risk lesions [15e17]. We sought to evaluate
the sensitivity and specificity of MRI-guided biopsy in
diagnosing cancerous and high-risk lesions by initiating
a retrospective study of 142 women who underwent this
procedure for lesions that were not demonstrated on
mammography or ultrasound. We conclude that breast MRI-
guided core biopsy is an important and relevant cancer
detection tool that can and should be applied to community
hospitals and outpatient facilities.
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